Oncology News International April 2009 Vol. 18 No. 4

Publication
Article

Cover Story

Optimal use of aromatase inhibitors comes into focus

Masters of hematology and oncology: David Alberts, MD

DEPARTMENTS

News & Analysis

Pharmaceutical mergers raise fears of treatment pipeline pruning

Prophylaxis fends off life-threatening invasive fungal infections

MR spectroscopy separates brain tumor recurrence from radiation necrosis

Medicare approves coverage of FDG-PET scans for 11 cancers

Cancer Care: Practice & Policy

Two major studies add fuel to fire of PSA controversy

Focus on Prostate Cancer

Evidence grows for value of high-field MRI in prostate cancer Rx

Most prognostic prostate cancer markers lack clinical utility

Focus on Colon Cancer

Minority groups protest CMS rejection of CT-based colon cancer screening

Focus on Hematology

Clear-cut evidence for routine use of ESA agents remains elusive

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC

Russ Conroy
November 25th 2024
Article

Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Site Logo

SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma

American Society for Transplantation and Cellular Therapy
November 25th 2024
Article

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma

Tim Cortese
November 25th 2024
Article

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation

Tim Cortese
November 22nd 2024
Article

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.